Comparison of Estramustine Phosphate, Methotrexate and cis-Platinum: in Patients with Advanced1 Hormone Refractory Prostate Cancer
Authors:
- 1 May 1983
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 129 (5) , 1001-1006
Abstract
In this clinical trial of men with advanced prostatic cancer no longer responsive to hormone therapy 189 were randomized to receive estramustine phosphate, methotrexate or cis-platinum. Response evaluations were done in 158 cases. Objective response rates (complete, partial or stabilization of disease) were 34 per cent for estramustine phosphate, 36 per cent for cis-platinum and 41 per cent for methotrexate. Subjective parameters indicated a substantial advantage for pain improvement with methotrexate or cis-platinum over estramustine phosphate. Probabilities of continued response indicated some advantage for methotrexate and median response durations at this time were twice as long for methotrexate (32 weeks) as for cis-platinum (16 weeks), with estramustine phosphate intermediate (23 weeks). Survival rates for the original treatment randomization groups were not different at this time. Side effects of estramustine phosphate consisted primarily of nausea and vomiting and/or anorexia but to a lesser extent than with cis-platinum. These effects were somewhat less for methotrexate, for which the major side effects were stomatitis and leukopenia, as well as hepatic toxicity reflected by elevated serum glutamic oxaloacetic transaminase levels. Other side effects of cis-platinum were less than for methotrexate (no stomatitis), except for signs of renal toxicity (elevations in blood urea nitrogen and serum creatinine), which were greater. Methotrexate had a relatively high level of activity against metastatic, progressive, hormone nonresponsive prostatic cancer, with side effects that were substantial but manageable.Keywords
This publication has 17 references indexed in Scilit:
- A Comparison of Hydroxyurea, Methyl-chloroethyl-cyclohexy-nitrosourea and Cyclophosphamide in Patients With Advanced Carcinoma of the ProstateJournal of Urology, 1981
- Comparison of Estramustine Phosphate and Vincristine Alone or in Combination for Patients with Advanced, Hormone Refractory, Previously Irradiated Carcinoma of the ProstateJournal of Urology, 1981
- Methotrexate: An active drug in bladder cancerCancer, 1981
- The Use of Estramustine and Prednimustine Versus Prednimustine Alone in Advanced Metastatic Prostatic Cancer Patients Who Have Received Prior IrradiationJournal of Urology, 1979
- Comparison of Procarbazine, Imidazole-Carboxamide and Cyclophosphamide in Relapsing Patients with Advanced Carcinoma of the ProstateJournal of Urology, 1979
- A Comparison of Estramustine Phosphate and Streptozotocin in Patients with Advanced Prostatic Carcinoma Who Have Had Extensive IrradiationJournal of Urology, 1977
- The Continued Evaluation of the Effects of Chemotherapy in Patients with Advanced Carcinoma of the ProstateJournal of Urology, 1976
- Pontine Glioma1974
- Adjuvant Methotrexate and Citrovorum-Factor Treatment of Osteogenic SarcomaNew England Journal of Medicine, 1974
- Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancerCancer, 1972